Adaptive Biotechnologies (ADPT)

• Market cap: $1.12B
• 1 day: 1.08%
• 5 days: -10.81%
• 1 month: -7.28%
• 3 months: 21.32%
• 6 months: 49.60%
• Year to date: 21.32%
• 1 year: 141.48%
• 5 years: -72.70%
• 10 years: -84.54%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Employees: 619

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 23

47% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 45

16% more capital invested

Capital invested by funds: $737M [Q3] → $858M (+$121M) [Q4]

10% more funds holding

Funds holding: 187 [Q3] → 206 (+19) [Q4]

9% more call options, than puts

Call options by funds: $178K | Put options by funds: $163K

0.62% less ownership

Funds ownership: 97.64% [Q3] → 97.03% (-0.62%) [Q4]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $9 20% upside
• Avg. target: $10.67 42% upside
• High target: $12 60% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Goldman Sachs Salveen Richter 24% 1-year accuracy 4 / 17 met price target	20% upside $9	Buy Upgraded	21 Mar 2025
Piper Sandler David Westenberg 44% 1-year accuracy 19 / 43 met price target	46% upside $11	Overweight Reiterated	20 Feb 2025
Scotiabank Sung Ji Nam 12% 1-year accuracy 3 / 25 met price target	60% upside $12	Sector Outperform Maintained	13 Feb 2025